Featured Research

from universities, journals, and other organizations

Agent selectively targets malignant B cells in chronic leukemia, study shows

Date:
May 4, 2011
Source:
Ohio State University Medical Center
Summary:
A new experimental drug called PCI-32765 selectively kills the cancer cells that cause chronic lymphocytic leukemia (CLL), according to a new study. The study shows that the agent selectively kills the malignant B lymphocytes that cause CLL. This is important, the researchers say, because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes. A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients.

A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).

Related Articles


The study shows that the experimental agent PCI-32765 selectively kills the malignant B lymphocytes that cause chronic lymphocytic leukemia (CLL).

The researchers say the findings, published online in the journal Blood, are important because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes.

T lymphocytes and B lymphocytes make up the adaptive immune system. When CLL treatment destroys them both, patients become highly susceptible to life-threatening infections.

"A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients," says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC -- James.

"Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL," says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.

The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:

  • The agent specifically targets an important signaling molecule called Bruton's tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
  • The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
  • It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-a, and stromal-cell contact.

Byrd is the D. Warren Brown Chair of Leukemia Research.

Funding from The Leukemia and Lymphoma Society, the National Cancer Institute and The D. Warren Brown Foundation supported this work.

Other researchers involved in this study were Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones and Kristie A. Blum of The Ohio State University; and Joseph J. Buggy and Ahmed Hamdy of Pharmacyclics, Inc.

Financial disclosure: Joseph J. Buggy and Ahmed Hamdy are employees of Pharmacyclics, Inc. and both have financial interests in PCI-32765 development.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. E. M. Herman, A. L. Gordon, E. Hertlein, A. Ramanunni, X. Zhang, S. Jaglowski, J. Flynn, J. Jones, K. A. Blum, J. J. Buggy, A. Hamdy, A. J. Johnson, J. C. Byrd. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 2011; DOI: 10.1182/blood-2011-01-328484

Cite This Page:

Ohio State University Medical Center. "Agent selectively targets malignant B cells in chronic leukemia, study shows." ScienceDaily. ScienceDaily, 4 May 2011. <www.sciencedaily.com/releases/2011/05/110503133044.htm>.
Ohio State University Medical Center. (2011, May 4). Agent selectively targets malignant B cells in chronic leukemia, study shows. ScienceDaily. Retrieved April 21, 2015 from www.sciencedaily.com/releases/2011/05/110503133044.htm
Ohio State University Medical Center. "Agent selectively targets malignant B cells in chronic leukemia, study shows." ScienceDaily. www.sciencedaily.com/releases/2011/05/110503133044.htm (accessed April 21, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, April 21, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Humanoid Robot Can Recognise and Interact With People

Humanoid Robot Can Recognise and Interact With People

Reuters - Innovations Video Online (Apr. 20, 2015) An ultra-realistic humanoid robot called &apos;Han&apos; recognises and interprets people&apos;s facial expressions and can even hold simple conversations. Developers Hanson Robotics hope androids like Han could have uses in hospitality and health care industries where face-to-face communication is vital. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Labour Party Warns Britain's Health Service 'on Life Support'

Labour Party Warns Britain's Health Service 'on Life Support'

AFP (Apr. 20, 2015) Britain&apos;s opposition Labour Party Monday claimed the National Health Service (NHS) was &apos;on life support&apos; as it turned its attention to the state-run service, which is a key issue for the UK&apos;s May 7 general election. Video provided by AFP
Powered by NewsLook.com
Sierra Leone Students Back to School After Long Ebola Closure

Sierra Leone Students Back to School After Long Ebola Closure

Reuters - News Video Online (Apr. 20, 2015) After an eight-month break, children in Sierra Leone return to school for the first time since the beginning of the Ebola outbreak. Nathan Frandino reports. Video provided by Reuters
Powered by NewsLook.com
Teen E-Cigarette Use Triples, Government Debates Regulations

Teen E-Cigarette Use Triples, Government Debates Regulations

Newsy (Apr. 19, 2015) The Centers for Disease Control and Prevention says in 2014, 13.4 percent of high school students reported smoking an e-cigarette within 30 days. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins